BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 38683349)

  • 1. Synthesis and preclinical evaluation of
    Hou H; Lin Y; Pan Y; Ma Y; Hou G; Sun X; Gao F
    Eur J Med Chem; 2024 May; 274():116545. PubMed ID: 38823263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of
    Ling SW; de Jong AC; Schoots IG; Nasserinejad K; Busstra MB; van der Veldt AAM; Brabander T
    Eur Urol Open Sci; 2021 Nov; 33():61-71. PubMed ID: 34632423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/CT With
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties.
    Hou H; Pan Y; Wang Y; Ma Y; Niu X; Sun S; Hou G; Tao W; Gao F
    Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38683349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Linker Modification on Tumor-to-Kidney Contrast of
    Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108
    [No Abstract]   [Full Text] [Related]  

  • 7. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
    Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
    J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improve the Biodistribution with Bulky and Lipophilic Modification Strategies on Lys-Urea-Glu-Based PSMA-Targeting Radiotracers.
    Cai P; Tang S; Xia L; Wang Y; Liu Y; Feng Y; Liu N; Chen Y; Zhou Z
    Mol Pharm; 2023 Feb; 20(2):1435-1446. PubMed ID: 36696174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current role of PSMA-PET imaging in the clinical management of prostate cancer.
    Georgakopoulos A; Bamias A; Chatziioannou S
    Ther Adv Med Oncol; 2023; 15():17588359231208960. PubMed ID: 38028141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, Preclinical Evaluation, and First-in-Human PET Study of [
    Chen Y; Zhang X; Ni M; Gao X; Wang X; Xie Q; Zhang J; Cui M
    J Med Chem; 2023 Sep; 66(18):13332-13345. PubMed ID: 37708404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.
    Bergengren O; Pekala KR; Matsoukas K; Fainberg J; Mungovan SF; Bratt O; Bray F; Brawley O; Luckenbaugh AN; Mucci L; Morgan TM; Carlsson SV
    Eur Urol; 2023 Aug; 84(2):191-206. PubMed ID: 37202314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Event-free survival after
    Ceci F; Rovera G; Iorio GC; Guarneri A; Chiofalo V; Passera R; Oderda M; Dall'Armellina S; Liberini V; Grimaldi S; Bellò M; Gontero P; Ricardi U; Deandreis D
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3257-3268. PubMed ID: 35217883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.
    Çermik TF; Ergül N; Yılmaz B; Mercanoğlu G
    Clin Nucl Med; 2022 Apr; 47(4):e333-e339. PubMed ID: 35085165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advancements in
    Piron S; Verhoeven J; Vanhove C; De Vos F
    Nucl Med Biol; 2022; 106-107():29-51. PubMed ID: 34998217
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.